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Absorption, Biotransformation, and
Storage of Halothane
by Duncan A. Holaday*
Current knowledge of the quantitative aspects of biotransformation of halothane and the fate of its
metabolites are reviewed. Absorbed quantities ofthe inhalation anesthetic average 12.7 and 18 g during 1
and 2 hr, respectively, of anesthesia. Reported fractions of halothane recovered as urinary metabolites
range from 10 to 25%. An analysis ofreports ofbromide ion accumulation in plasma during and following
anesthesia suggests that metabolism of halothane continues for 20-40 hr after exposure and that 22-24%
of absorbed halothane is metabolized following 8 hr of anesthesia. Half-times for excretion of
trifluoroacetic acid (TFA), a principal urinary metabolite of halothane, tend to confirm that biotransfor-
mation proceeds for 2 to 3 days following exposure. Other urinary metabolites which occur in small
amounts include a dehydrofluorinated metabolite of halothane conjugated with L-cysteine and N-
trifluoroacetyl-n-ethanolamine, both of which are evidence of the occurrence of reactive intermediates
during the metabolism of halothane. Support for free radical formation has come from in vivo and in
vitro demonstrations ofstimulation oflipoperoxidation ofpolyenoic fatty acids by halothane. Irreversible
binding ofhalothane metabolites to microsomal proteins and phospholipids has been shown to depend on
the microsomal P-450 cytochrome system. Irreversible binding is increased by microsomal enzyme induc-
tion and by anaerobic conditions. Hypoxia increases irreversible binding to phospholipids, augments the
release of inorganic fluoride and is followed by centrilobular hepatic necrosis. It is concluded that
one-fourth to one-half of halothane undergoes biotransformation in man. One fraction is excreted as
trifluoroacetic acid, chloride and bromide. A second fraction is irreversibly bound to hepatic proteins and
lipids. Under anaerobic conditions fluoride is released, binding to phospholipids is increased, and hepatic
necrosis may occur.
The purpose of this communication is to review
current knowledge of the quantitative aspects of
biotransformation of halothane and the fate of its
metabolites.
Absorbed Dose
In order to establish anesthesia as soon as possi-
ble, inhalation anesthesia is commonly initiated by
using overpressure, i.e., an inspired concentration
higher than the minimum alveolar concentration
(MAC) (1) required to maintain anesthesia. Pro-
gressive reduction of the inspired concentration is
employed to maintain a constant alveolar (and arter-
ial blood) concentration. The whole body cumulative
uptake depends on the solubility ofthe anesthetic in
all the tissues, the volumes of the tissues and the
rates of blood flow to the various tissues. Lowe (2)
has shown, however, that the cumulative uptake
Qn) required to achieve and maintain a constant
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plane of anesthesia can be approximated by the ex-
pression
Qan = 2 x 1.3MAC X XblQti
where X,,, is the blood/gas partition coefficient ofthe
anesthetic, Q is the cardiac output, and t is the du-
ration of the exposure.
Reported cumulative uptakes (3-7) for inhalation
anesthetics average about 18 g during 2 hr of anes-
thesia (Table l) or, by the square-root-of-time rule
given above to estimate, 12.7 g during 1 hr of anes-
thesia. These quantities of drug absorbed during
anesthesia set the anesthetics apart from other
drugs and atmospheric pollutants, and prompt spe-
cjlal consideration with respect to biotransformation
and potential toxicity.
Factors Determining Extent
of Biotransformation
The volatile anesthetics are metabolized to a
greater or lesser extent, depending on their solubil-
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Total uptake Exposure
Anesthetic n Avg. Range (avg.), min. Reference
Isoflurane 9 18.1 10-24 130 (3)
Enflurane 7 18.4 15-32 115 (4)
Fluroxene 9 32.0 18-45 142 (5)
Halothane 2 9.2 7.3, 11.1 75 (6)
Methoxyflurane 12 18.1 7.6-31 138 (7)
ity in body fluids and their chemical stability. A
simulation study tested the influence of solubility
(8). Based on the observation by Sawyer- et al. (9)
that the fraction metabolized of halothane in blood
peifusing the liver of miniatur-e swine increatses as
the concentration decr-eases, a nonlinear- model was
adopted which assumed that, at a given molar- con-
centration in artetrial blood, all anesthetics are bio-
transformed to the same extent as halothane (Fig.
1). By inserting this term into the expression for
uptake, distribution, and excretion to inert drugs in
a five-compartment model of man, the predicted
fractions ofabsorbed dose and millimolar- quantities
of the anesthetics which aire subject to biotransfor-
mation were calculated (Table 2). It appeairs that
the fraiction of dose metabolized increases slightly
with time, whereas the molar- quantity increases
greatly. Lipid, rather than blood solubility, deter-
mines the fraction metabolized, whereas the molar
quantity metabolized reflects the blood solubility.
Table 3 reveals, in the cases of isoflurane and en-
Table 2. Simulated metabolism by a nonlinear model.0
Anesthetic
Anesthetic metabolized,
metabolized. % mmoleb
Anesthetic XbC Xfd 1 hr 4 hr 8 hr I hr 4 hr 8 hr
Fluroxene 1.4 34 12 13 14 13 30 48
Diethyl ether 13. 50 15 12 13 73 110 140
Isoflurane 1.4 68 16 18 20 12 30 50
Enflurane 1.9 70 17 18 20 11 26 42
Halothane 2.4 155 24 26 30 14 36 59
Methoxyflurane 11. 670 51 52 54 27 64 100
aData of Feingold and Holaday (7).
bFor various durations of anesthesia.
cBlood-gas partition coefficient.
dFat-gas partition coefficient.
flurane, that chemical stability must play an impor-
tant role in limiting biotransformation, since these
drugs are metabolized much less than is predicted
by the model. Predictions for fluroxene, halothane,
and methoxyflurane, on the other hand, appear to
be substantiated by the experimental data given in
Table 3.
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FIGURE 1. Nonlinear model. Simulated relationship between
fraction metabolized by liver and molar arterial anaesthetic
concentration at MAC. Reproduced from Feingold and
Holaday (8) by kind permission of Dr. Feingold and the pub-
lishers.
Other factors which tend to increase the fraction
of the dose metabolized include obesity (5) and ex-
posure to microsomal inducing agents (10). Genetic
factors play an important role, since mean intra-
twin difference in the quantity ofhalothane metabo-
lites excreted in 24 hr was 11.7% for identical twins
as compared to 31% for fraternal twins (11).
Excretion
The production of metabolites of halothane by
man have been measured mainly in urine and blood;
sweat and feces have been shown to account for
less than one percent of the dose (10). Stier et al.
(12) demonstrated increased bromide excretion in
urine. Rehder (6) and associates accounted for 12%
excreted as trifluoroacetic acid (TFA) by two pa-
tients. Cascorbi (10) confirmed that TFA was the
principal fluorine-containing urinary metabolite of
Table 3. Fate of inhalation anesthetics in man.
Recovered, % Not
Anesthetic n Exhaled Metabolites Total recovered, % Reference
Isoflurane 9 95 0.17 95 5 ( 3)
Enflurane 6 83 2.4 85 15 ( 4)
Fluroxene 9 58 10 68 32 ( 5)
Halothane 1 46a 25 71 29 (10)
Methoxyflurane 12 19 44 63 37 ( 7)
aAssumes 80% exhaled in 5 hr.
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ihalothane and amounted to 10.6 to 24.8% (avg. 17%)
of an intravenously infused dose in unanesthetized
volunteers, and about 30% less following anes-
thesia. Anesthesia also decreased the half-time of
urinary metabolites in one subject from 55 to 45 hr.
In their most carefully controlled experiment, 62%
of the injected dose was recovered, 36.8% in ex-
haled air, 24.8% in urine, 0.336% in sweat and
feces. Recovery in exhaled air was reported for 5 hr
only; on assuming that 80% of the amount to be
exhaled was exhaled in 5 hr, recover-y can be cor-
rected to 71%. In other experiments 58 to 74% was
recovered. This is consistent with OUr findings in
balance studies of other anesthetics (13) (Table 3).
Exhaled air was sampled for periods of 5-10 days
and urine was collected for up to 14 days. Essen-
tially the same methods of collection were used in
all studies. These data suggest that the larger the
fraction recovered as urinary metabolites, the larger
the fraiction that cannot be accounted forias exhaled
unaltered drug and urinary metabolites.
Accumulation of Metabolites in
Body Fluids
An alternative way of accounting for extent of
biotransformation is to measure the accumulation
of metabolites in body fluids. This requires mea-
surement of the metabolite in plasma, and knowl-
edge of the binding characteristics, the apparent vol-
ume of distribution and the time constants for dis-
tribution and excretion of the metabolite. Bromide
ion release from halothane presents a( reasonable
index for following halothane degradation. Bromide
is a principal metabolite, is distributed mainly in the
chloride space, and is excreted very slowly by the
kidney (t012 = 12-22 days).
Plasma bromide concentrations during and fol-
lowing anesthesia have been studied (14-17)
Tinker and Van Dyke (14) found that peak plasma
bromide concentration rose linearly in patients at a
rate of 26 mg/I. per MAC hour. The total dose of an
anesthetic is the sum ofthe amounts taken up by the
rapidly perfused visceral organs, muscle, slowly
perfused aqueous tissues, fat, and the amount
metabolized (13). The viscera achieve equilibrium
in 20 min and acccount for 72% of cumulative total
body uptake at that time. Muscle and other lean
body tissues account for 16% of the dose alt 20 min
and continue to absorb at a slow, decrementing rate
for several houL-s, while fat continuLes to absorb drug
at an ailmost constant rate for as long as anesthesia
lasts (2). The anesthetics are released in the same
order. Accor-dingly, Tinker's obser-vation of a linear
rate of rise of bromide in plasma suggests thait pro-
longed release of halothane from the slowly ex-
changing compairtments, rather than the total ab-
sorbed dose, determines the rate and extent of bio-
transformation.
Relatively little bromide is released dul-ing anes-
thesia (15, 16) (Table 4). The major- portion of
plasmCa btromide accrues during 20-40 hr following
the end of anesthesia (15-17). This appr-oximates
the half-time for depletion of the slowest exchang-
ing storage compartment.
Knowledge of the half-time of urinary tri-
fluoroacetic acid also provides an opportunity for
estimating when biotransformation occurs, during
exposure when blood concentrations are high, or
during recovery when slow concentrations are
maintained by diffusion from slowly perfused lipid
storage areas. Holaday and Cunnah (18) found that
the half-time for urinary excretion of TFA by nor-
mal volunteers is 16 hr. The half-times for excretion
ofTFA by patients calculated from the data of Reh-
der et al. (6) was 58 hr and from the data ofCascorbi
et al. (10) on volunteers, the half-times cover a range
from 39 to 61 hr. If it is assumed that diffusion of
TFA out of cells occurs within a few hours, the dif-
ference between these half-times suggests that the
predominant portion of biotransformation occurs
after anesthesia during the first 2 or 3 days following
anesthesia.
Biotransformation and Toxicity
Jaundice and hepatic necrosis are rare toxic reac-
tions which follow halothane anesthesia. The
mechanism responsible for this has eluded any
proven explanation but consistently has been linked
to biotransformation, and covalent binding to vital
subcellular macromolecules has been implicated
Table 4. Bromide production during and following halothane anesthesia.
Subjects Exposure Change (Br-)p Dose metabolized, %a Reference
8 patients 1.5%, 20 min 2.3/30 min 0.68 (15)
22.85/20-40 hr 11.9
7 volunteers 1.0o, 6.6 hr 200/48 hr 21.8 (17)
7 volunteers l.0%o, 8.9 hr 12.8/8 hr 0.55 (16)
216/40 hr 24.4
aAbsorbed dose calculated after Lowe (1); bromide space taken to be 0.275 1./kg body weight.
December 1977 167(19). TFA and the concurrently formed metabo-
lites, Br- and C1- are essentially nontoxic, and
TFA has been shown not to bind (19, 20).
Cohen et al. (21) have demonstrated the occur-
rence of organic metabolites other than TFA in
human urine. They collected urine from heart-
donors for 6 hr following infusion of "4C-labeled
halothane. They were able to identify three large
radioactive peaks and several smaller peaks by
anion-exchange column chromatograph. The
largest and most acidic peak dominating later urines
proved to be trifluoroacetic acid. A less acid frac-
tion which appeared only in early samples was iden-
tified as a thio ether of N-acetylcysteine and a
dehydrofluorinated metabolite of halothane;
N-acetyl-S-(2-bromo-2-chloro-1,1-difluoroethyl)-
L-cysteine. A third, neutral, water-soluble fraction
appearing in constant, low concentration was
N-trifluoroacetyl-N-ethanolamine. Trace quan-
tities of the two conjugated metabolites were also
identified in the urines of five normal volunteers
given tracer dose of 14C-labeled halothane. The
two conjugated compounds imply the occurrence of
reactive intermediates in the metabolism of
halothane.
Brown and his associates (22, 23) have explored
the possibility that free-radical intermediate
metabolites of halothane stimulate lipoperoxidation
of polyenoic fatty acids. These are components of
the phospholipids which contribute to the structure
of the endoplasmic reticulum. Their disruption
could cause interference with vital functions of the
microsomal enzyme system. In phenobarbital pre-
treated rats, but not in non-induced animals,
halothane increased diene conjugate formation, as
did chloroform but not fluroxene or diethyl ether
(22). Chloroform depleted glutathione and caused
centrilobular liver necrosis, whereas halothane did
not (23). These observations provide some support
for Green's conclusion from a retrospective clinical
study that induced patients are not at more risk
from halothane anesthesia than non-induced pa-
tients.
Van Dyke and his associates have elucidated the
locations and determinants of irreversible binding
ofhalothane metabolites in rat liver (19, 20, 24-27).
Binding occurs in the microsomes (19), is inhibited
by carbon monoxide (19, 24) and SKF-525A (25),
requires NADPH (24), is increased by pretreat-
ment with phenobarbital (19) and polychlo-
robiphenyls (25), but not by methylcholanthrene
(19, 25), and is greatly accelerated by anaerobic
conditions (24, 26, 27). Under aerobic conditions in
vivo, most binding is to microsomal proteins and
phospholipids (24, 27). In animals breathing
halothane in 7% oxygen, total binding was doubled
and the lipid/protein binding ratio increased more
than fourfold. Fluoride release, normally negligible,
increased twentyfold in surviving animals and, in
animals which died during exposure, to 70 mmole/l.
in plasma, a 100-fold increase (27).
14C- and 36Cl-labeled halothane bound equally to
phospholipids under anoxic conditions (26), sug-
gesting that the chlorine atom remained attached to
the halothane moiety bound to the lipids. It is pos-
sible that this moiety is the same dehydrofluori-
nated metabolite that Cohen (21) found conjugated
to L-cysteine in human urine.
Wood et al. (26) confirmed Brown's reports (22,
23) of lipoperoxidation ofpolyenoic acids in oxyge-
nated in vitro incubations of induced microsomes
with halothane. In anaerobic incubations, diene
conjugate formation progressed as under aerobic
conditions, but peroxidation was inhibited, and
binding of a halothane metabolite to phospholipids
was increased greatly (26).. This suggests that ox-
ygen binds more readily to diene conjugates than a
halothane intermediate. Oxygen may also oxidize
the halothane intermediate to TFA before it can
bind.
An Animal Model of Halothane
Hepatotoxicity
Most exposures of experimental animals to
halothane have been benign. However, even when
exposures have been conducted under severe
hypoxia or following multiple, prolonged exposures
of phenobarbital-pretreated animals and toxicity
has been evident (28), the centrilobular necrosis
which pathologists associate with clinical halothane
hepatitis (29) has not been mimicked.
Recently Sipes and Brown (30) have proposed an
animal model of halothane hepatic necrosis. Cen-
trilobular hepatic necrosis was demonstrable in
Aroclor 1254 [a mixture of polychlorinated
biphenyls (PCB)]-pretreated rats 24 hr after expo-
sure to 1% halothane in oxygen for 2 hr. In vitro
binding of "4C from labeled halothane to mi-
crosomal proteins and lipids was also shown to be
enhanced by PCB pretreatment in a pattern similar
to that obtained by incubating microsomes with
halothane in an atmosphere of nitrogen. Since
PCBs are known to cause neoplastic changes in liv-
ers of mice (31), and halothane reduces hepatic
blood flow (32), the effect may result from a combi-
nation ofenhanced and altered microsomal activity,
stagnant hypoxia, and the presence of other reac-
tive intermediate metabolites.
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The foregoing observations suggest that patients
metabolize one-fourth to one-half of absorbed
halothane. One fraction is excreted in the urine as
triflloroacetic acid, bromide, and chloride. Under
normal conditions, a second fraction undergoes ir-
rever-sible binding to microsomal proteins and lipids
without interfering with cell functions. Under
anaerobic conditions, a third pathway of biotrans-
formation is activated, resulting in release of
fluoride and increased binding to phospholipids.
Hepatotoxicity may be associated with this third
reaction.
This study was supported in part by U.S. Public Health and
NIH grants 16498-08 and RR536314.
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